The drugmakers, in turn, failed to ban doctors with repeated violations from prescribing the drugs, the records show. Even the FDA noted in 2016, the industry group’s policy was unclear on what actions would lead to suspension or removal. One doctor continued in the program even after he was indicted by a federal grand jury for healthcare fraud and distributing controlled substances.